Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439679 | 1.00 | HCAR2 (0.56) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL8459558 | 0.88 | HCAR2 (0.53) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL6049911 | 0.88 | HCAR2 (0.53) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL6049907 | 0.88 | HCAR2 (0.53) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL2045541 | 0.88 | HCAR2 (0.48) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL8459101 | 0.85 | HCAR2 (0.50) | HCAR2MAPTMAPK1PRKCA | |
| SCHEMBL8662436 | 0.85 | HCAR2 (0.46) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL8461078 | 0.83 | HCAR2 (0.51) | HCAR2TSHRMAPTMAPK1 | |
| SCHEMBL9576356 | 0.83 | HCAR2 (0.51) | HCAR2TSHRMAPTMAPK1 | |
| SCHEMBL3889388 | 0.80 | S1PR1 (0.42) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333816-A1 | LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS | Midas Pharma GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| CN-116947642-A | Long-residence polyalcohol hair care raw material molecule and preparation and application thereof | 江南大学 | 2023-10-27 | — | — | CN | claimed |
| WO-2022234139-A1 | LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS | Midas Pharma GmbH (DE) | 2022-11-10 | — | — | WO | claimed |
| EP-4085903-A1 | MINI-TABLET CONTAINING LOSARTAN FOR PEDIATRIC APPLICATIONS | Midas Pharma GmbH (DE) | 2022-11-09 | — | — | EP | claimed |
| US-20200289523-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION | Midas Pharma GmbH (DE) | 2020-09-17 | — | — | US | claimed |
| EP-3429561-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION. | Midas Pharma GmbH (DE) | 2019-01-23 | — | — | EP | claimed |
| WO-2017158094-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION. | K.H.S. PHARMA HOLDING GMBH (DE) | 2017-09-21 | — | — | WO | claimed |
| EP-3219309-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION | K.H.S. Pharma Holding GmbH (DE) | 2017-09-20 | — | — | EP | claimed |
| WO-2014029953-A1 | HOT MELT EXTRUDED (HME) PHARMACEUTICAL COMPOSITION OF CINACALCET | CIPLA LIMITED (IN) | 2014-02-27 | — | — | WO | claimed |
| US-12605340-B2 | Extended release composition of 2-(2-Aminothiazol-4-yl)-N-[4-(2{[(2R)-2-hydroxy-2-phenylethyl] amino} ethyl) phenyl] acetamide | ZIM LABORATORIES LIMITED (IN) | 2026-04-21 | — | — | US | disclosed |
| EP-4135668-B1 | SOLID ORAL DOSAGE FORM COMPRISING POMALIDOMIDE | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2024-04-17 | — | — | EP | disclosed |
| EP-4333816-A1 | LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS | Midas Pharma GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-116947642-A | Long-residence polyalcohol hair care raw material molecule and preparation and application thereof | 江南大学 | 2023-10-27 | — | — | CN | disclosed |
| EP-4225289-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE MANAGEMENT AND TREATMENT OF PAIN | CELLIX BIO PRIVATE LIMITED (IN) | 2023-08-16 | — | — | EP | disclosed |
| EP-3501502-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITIONS COMPRISING AMLODIPINE, RAMIPRIL AND ATORVASTATIN | Midas Pharma GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| EP-3429561-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION. | Midas Pharma GmbH (DE) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017158094-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION. | K.H.S. PHARMA HOLDING GMBH (DE) | 2017-09-21 | — | — | WO | disclosed |
| EP-3219309-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION | K.H.S. Pharma Holding GmbH (DE) | 2017-09-20 | — | — | EP | disclosed |
| CN-1946382-B | Fast Dissolving Formulations of Calcium Receptor Active Compounds | AMGEN INC | 2010-12-08 | — | — | CN | disclosed |
| CN-1946382-A | Fast Dissolving Formulations of Calcium Receptor Active Compounds | AMGEN INC (US) | 2007-04-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605340-B2 | Extended release composition of 2-(2-Aminothiazol-4-yl)-N-[4-(2{[(2R)-2-hydroxy-2-phenylethyl] amino} ethyl) phenyl] acetamide | ADRB2, ADRA2B, ADRB1 | HCAR2 845/4885TSHR 1428/4885TP53 4575/4885 |
| US-20200289523-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION | REN, AGT, ACE | HCAR2 545/4885TSHR 2203/4885TP53 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.